Aclarion announces availability of CEO shareholder letter

ACON•2026-07-29

U.S. market access and cash position

The company outlined its U.S. market access push through a PRIA Healthcare partnership and progress toward the CLARITY trial readout.

Aclarion reported $16.3 million in cash and no debt as of June 30, 2026, with cash runway into the second half of 2027.

CEO shareholder letter highlights scan volume growth and reimbursement progress

Aclarion announced the availability of a CEO shareholder letter covering the first half of 2026: CEO Shareholder Letter.

The letter cited 141% year-over-year scan volume growth and 71% sequential growth, with expanding Nociscan use in the U.S. and U.K. It also highlighted U.K. reimbursement momentum, including coverage by Vitality, AXA, and Aviva.

Sources

Aclarion announces availability of CEO shareholder letter

Publicnow

Aclarion announces availability of CEO shareholder letter

U.S. market access and cash position

CEO shareholder letter highlights scan volume growth and reimbursement progress

Related News

Peabody Q2 FY26 net loss widens to $90.6 million; revenue rises 12.7% to $1 billion

Allied Gold drops as sale to Zijin is terminated

Lighthouse Canton says memory-chip selloff diverges from earnings, flags opportunity to sell elevated volatility

Sources

Aclarion announces availability of CEO shareholder letter

Iveda partners with Primion to offer IvedaAI video analytics to European security customers

Cenovus raises 2026 production outlook as quarterly profit more than triples